Literature DB >> 25958817

Expectant management for men with early stage prostate cancer.

Christopher P Filson1, Leonard S Marks2, Mark S Litwin3.   

Abstract

Since the dissemination of prostate-specific antigen screening, most men with prostate cancer are now diagnosed with localized, low-risk prostate cancer that is unlikely to be lethal. Nevertheless, nearly all of these men undergo primary treatment with surgery or radiation, placing them at risk for longstanding side effects, including erectile dysfunction and impaired urinary function. Active surveillance and other observational strategies (ie, expectant management) have produced excellent long-term disease-specific survival and minimal morbidity for men with prostate cancer. Despite this, expectant management remains underused for men with localized prostate cancer. In this review, various approaches to the expectant management of men with prostate cancer are summarized, including watchful waiting and active surveillance strategies. Contemporary cancer-specific and health care quality-of-life outcomes are described for each of these approaches. Finally, contemporary patterns of use, potential disparities in care, and ongoing research and controversies surrounding expectant management of men with localized prostate cancer are discussed.
© 2015 American Cancer Society, Inc.

Entities:  

Keywords:  active surveillance; expectant management; prostate cancer; watchful waiting

Mesh:

Year:  2015        PMID: 25958817     DOI: 10.3322/caac.21278

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  19 in total

1.  Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells.

Authors:  Corena V Shaffer; Shengxin Cai; Jiangnan Peng; Andrew J Robles; Rachel M Hartley; Douglas R Powell; Lin Du; Robert H Cichewicz; Susan L Mooberry
Journal:  J Nat Prod       Date:  2016-01-19       Impact factor: 4.050

Review 2.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

3.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

4.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

Review 5.  Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology.

Authors:  Nima Nassiri; Shyam Natarajan; Daniel J Margolis; Leonard S Marks
Journal:  Urology       Date:  2015-07-10       Impact factor: 2.649

6.  Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer.

Authors:  Kathleen D Lyons; Hsin H Li; Emily M Mader; Telisa M Stewart; Christopher P Morley; Margaret K Formica; Scott D Perrapato; John D Seigne; Elias S Hyams; Brian H Irwin; Terry Mosher; Mark T Hegel
Journal:  Am J Mens Health       Date:  2016-07-07

7.  Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.

Authors:  Ely R Felker; Jason Wu; Shyam Natarajan; Daniel J Margolis; Steven S Raman; Jiaoti Huang; Fred Dorey; Leonard S Marks
Journal:  J Urol       Date:  2015-12-07       Impact factor: 7.450

Review 8.  Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis.

Authors:  Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Konstantinos Kontoangelos; Charalambos Papageorgiou; Ioannis P Anastasiou
Journal:  Curr Urol       Date:  2020-12-18

9.  Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.

Authors:  Ying-Li Lin; Qiu-Kui Deng; Yu-Hao Wang; Xing-Li Fu; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2015-12-19

10.  Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.

Authors:  Richard M Hoffman; Sarah L Mott; Bradley D McDowell; Sonia T Anand; Kenneth G Nepple
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-06-09       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.